MyEClinic
MyEClinic
Health Dictionary Find a Doctor

R-MINE regimen

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords: Rituximab-Mesna-Ifosfamide-Novantrone-Etoposide regimen

Overview

Overview

R-MINE regimen refers to a regimen consisting of rituximab, mesna, ifosfamide, mitoxantrone, and etoposide used to treat relapsed or refractory Hodgkin’s lymphoma and non-Hodgkin’s lymphoma.[1][2]

Regimen

Regimen

RRituximab

MMesna

IIfosfamide

NMitoxantrone (Novantrone)

EEtoposide

Indications

Indications

References

References

  1. ↑ 1.0 1.1 Fan Y, Huang ZY, Luo LH, Yu HF (2005). “[MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin’s lymphoma]”. Ai Zheng. 24 (12): 1503–6. PMID 16351801.
  2. ↑ “NCI Thesaurus”.
  3. ↑ “NCI Thesaurus”.

Looking for the patient version?

Back to the patient-friendly article

Imprint

Privacy Policy

Terms and Conditions

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH